Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ATF1 | P18846 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15018084 | 0.84 | KDM4E (0.50) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL30353376 | 0.83 | POLB (0.51) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17410229 | 0.83 | POLB (0.51) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL21679118 | 0.82 | CNR2 (0.51) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17583114 | 0.79 | POLB (0.50) | L3MBTL1ALDH1A1HPGDPOLBGAA | |
| SCHEMBL17113764 | 0.78 | POLB (0.49) | L3MBTL1ALDH1A1HPGDPOLBGAA | |
| SCHEMBL24792648 | 0.77 | ACSS2 (0.46) | L3MBTL1ALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL17315773 | 0.77 | GAA (0.51) | L3MBTL1ALDH1A1HPGDPOLBGAA | |
| SCHEMBL14330640 | 0.77 | POLB (0.48) | L3MBTL1ALDH1A1HPGDPOLBGAA | |
| SCHEMBL13199136 | 0.77 | TSHR (0.49) | ALDH1A1POLBKDM4EABCB11CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-19 | — | — | US | disclosed |
| EP-4034535-B1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2026-03-04 | — | — | EP | disclosed |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | NOVARTIS AG (CH) | 2026-02-10 | — | — | US | disclosed |
| US-20250066328-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025024663-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-114746414-B | Aza-quinoline compounds and uses thereof | 诺华公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4034535-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | Novartis AG (CH) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746414-A | Aza-quinoline compounds and uses thereof | 诺华公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021057853-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS AG (CH) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076968-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, SUZ12, NR3C1 | L3MBTL1 1856/4885ALDH1A1 1941/4885HPGD 3180/4885 |
| US-20250066328-A1 | PARP7 INHIBITORS | PARP1, PARP2, PARP8 | L3MBTL1 3024/4885ALDH1A1 1336/4885HPGD 1069/4885 |
| US-12544374-B2 | AZA-quinoline compounds and uses thereof | EZH2, NR3C1, SUZ12 | L3MBTL1 2535/4885ALDH1A1 1524/4885HPGD 3045/4885 |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | L3MBTL1 3269/4885ALDH1A1 808/4885HPGD 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.